I'd hate to be short Pall (NYSE:PLL),
as large companies in the filtration space often seem as close to
bulletproof as you can find in the market. So even though sell-side
analysts chronically overestimate Pall's free cash flow, investors
remain happy with a company that admittedly enjoys strong share and a
very lucrative channel of repeat business. While I think Pall's shares
remain overvalued, I don't have any particular reason to believe that
the shares will sell off dramatically, as the life sciences business
should be stable and the industrial business should start improving next
year.
Please read more here:
http://www.investopedia.com/stock-analysis/082913/pall-always-gets-benefit-doubt-pll-dci-entg-iex.aspx
No comments:
Post a Comment